Zacks Research Cuts Earnings Estimates for Bausch Health Cos

Bausch Health Cos Inc. (NYSE:BHC) – Zacks Research dropped their Q2 2027 EPS estimates for Bausch Health Cos in a report released on Monday, July 27th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.81 for the quarter, down from their prior forecast of $0.82. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.05 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q3 2027 earnings at $1.04 EPS, Q4 2027 earnings at $0.93 EPS, FY2027 earnings at $3.59 EPS, Q1 2028 earnings at $0.57 EPS, Q2 2028 earnings at $0.81 EPS and FY2028 earnings at $3.02 EPS.

A number of other research firms also recently weighed in on BHC. Weiss Ratings downgraded Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Royal Bank Of Canada decreased their price target on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a report on Monday, April 27th. Finally, Jefferies Financial Group upgraded Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Five analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Bausch Health Cos presently has a consensus rating of “Reduce” and a consensus price target of $8.00.

Bausch Health Cos Stock Up 1.2%

Shares of BHC opened at $4.49 on Tuesday. The business’s fifty day moving average price is $4.98 and its two-hundred day moving average price is $5.52. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of -1.38 and a beta of 0.42. Bausch Health Cos has a 52 week low of $4.33 and a 52 week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.37 billion.

Institutional Trading of Bausch Health Cos

Several institutional investors and hedge funds have recently made changes to their positions in the business. Caption Management LLC lifted its stake in shares of Bausch Health Cos by 101.1% in the 4th quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after purchasing an additional 405,789 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in shares of Bausch Health Cos by 12,589.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after purchasing an additional 4,910 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in shares of Bausch Health Cos by 6,661.2% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after purchasing an additional 5,329 shares during the period. Russell Investments Group Ltd. increased its holdings in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Camelot Portfolios LLC bought a new stake in Bausch Health Cos in the fourth quarter valued at about $59,000. Institutional investors own 78.65% of the company’s stock.

Insider Transactions at Bausch Health Cos

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the transaction, the director directly owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.